Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus IODIXANOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus IODIXANOL.
HYPAQUE-M,75% vs IODIXANOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Iodixanol is a nonionic, iso-osmolar iodinated contrast agent that attenuates X-rays, allowing visualization of vascular structures and organ parenchyma. It does not bind to or interact with specific receptors.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
Intravenous injection of 270-350 mg iodine/kg (0.5-1.0 mL/kg of 270 mg I/mL solution) for CT; 300-400 mg iodine/kg for angiography. Administer as bolus or infusion per procedure.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 mL/min), half-life may be prolonged up to 10-12 hours, requiring dose adjustment and monitoring.
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Primarily renal: approximately 97% of the administered dose is excreted unchanged in the urine within 24 hours via glomerular filtration. Less than 3% is excreted in feces via biliary elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent